Health News

Acomplia Rimonabant For Corpulence Treatment

Acomplia (Rimonabant) - Forcible weight loss and anti-obesity medication
Approximately two third of the population of all developed countries is either overweight or obese. Pudginess highly increases the risk of developing diabetes, cardiovascular disease and bounteous other fatal diseases. A collection of aids hold come and elsewhere to benefit clash obesity. Nevertheless, this health enigma is spreading its tentacles over most developed nations.
Besides calorie controlled diets and exercises, there are weight loss aids such as exercising machines, herbal potions, over-the-counter remedies, and prescription drugs. Outside of all these options, exclusive prescription drugs are clinically proven and hence lousy with cats prefer them. One such prescription narcotic is Acomplia rimonabant.
About Acomplia Slimming and weight loss pills - its manufacturer
Acomplia rimonabant is manufactured by French pharmaceutical corporation "Sanofi-Aventis" and it is the fresh weight loss drug. Acomplia works by blocking the CB1 receptor, one of two receptors fix in physiological development called the Endocannabinoid Operation (EC System). It is believed that EC step plays a critical role in the statute of cookery intake and compel expenditure.
Acomplia works by selectively targeting and blocking the CB1 receptors, helping stabilize the over-activation of the EC course and managing famine cravings in a more advantageous way.
Medical tests on Acomplia and its attainment rates
Acomplia diet pills are clinically tested and proven to work. In a clinical check named RIO programme i.e. Rimonabant in Fatness program, aggrandized than 6600 patients across four stage III studies: RIO-Diabetes, RIO-Lipids, RIO-North America and RIO-Europe were involved. This program lasted from 2001 to 2005 and in the third quarter of 2006 itself, Acomplia diet pills received approval when its fame rates were seen.
Available dosage strength
Acomplia should be taken once in a day, before breakfast. Usually recommended Acomplia dosage is 20mg which should be swallowed with one abundant glass of water.
Ingredients of Acomplia
The active ingredient in Acomplia is rimonabant. It is a CB1 receptor antagonist that works by blocking decided neurotransmitters in the brain.
Side factor of Acomplia
Acomplia has definite babe side effects. However, these side stuff are transient in bag and hardihood elsewhere once your thing adjusts to the medication.
  • Infections (Upper respiratory tract infection, Gastroenteritis)
  • Mood alterations
  • Memory loss
  • Dizziness, headache, irritability
  • Nausea, diarrhea, vomiting
  • Hot flush
  • Skin disorders
  • Tendonitis, muscle cramps or spasms
  • Asthenia/fatigue influenza
Rare side object of Acomplia
  • Panic symptoms, exasperation and emotional disorder
  • Lethargy
  • Hiccups
  • Night sweats
Online availability of Acomplia
30 Nov 2008 23:00:27

New Sanofi CEO Expected to Map Fresh Course on Developing Drugs - Wall Street Journal

New Sanofi CEO Expected to Map Fresh Course on Developing Drugs Wall Street Journal - One example: the obesity pill Acomplia , which Sanofi continued to develop years after signs emerged that the drug had negative psychological side effects. ... Viehbachers First Day On The Job At Sanofi Viehbacher, Passed Over at Glaxo, Takes Sanofi Reins (Update1) What will Viehbacher bring to Sanofi?
27 Nov 2008 08:36:16

Anti-obesity agent Acomplia is withdrawn - Healthcare Republic

Anti-obesity agent Acomplia is withdrawn Healthcare Republic - The marketing authorisation for Acomplia (rimonabant) has been suspended after a European Medicines Agency (EMEA) review. The EMEA's Committee for Medicinal ...
17 Nov 2008 11:12:53

UPDATE 1-Solvay ends research on obesity drug - Reuters

UPDATE 1-Solvay ends research on obesity drug Reuters - Acomplia , which led the field, had already been withdrawn from the European market last month after being linked to mental disorders. ...
17 Nov 2008 05:14:21

Solvay discontinues research into potential obesity compound - Hays Pharma

Pharma Times (registration) Solvay discontinues research into potential obesity compound Hays Pharma, UK - The company's investigational compound SLV319 was in phase-two development and, according to the company, recent results had "confirmed its clinical ... Tough regulatory climate sees Solvay end trials of SLV319
13 Nov 2008 21:17:07

Firm stops trials of obesity drug - Healthcare Republic

Firm stops trials of obesity drug Healthcare Republic - Sanofi-Aventis has discontinued all trials of its anti-obesity drug rimonabant ( Acomplia ), which was suspended by the European Medicines Agency last month. ...
13 Nov 2008 11:03:00

Development of rimonabant and CP-945598 for obesity is discontinued - Drug Topics Magazine

Development of rimonabant and CP-945598 for obesity is discontinued Drug Topics Magazine, NJ - ... European marketing authorization of rimonabant (European brand name Acomplia ) be suspended because of an increased risk of psychiatric adverse events. ...
07 Nov 2008 05:45:55

Competitor Analysis: Cannabinoid CB1 Receptor Antagonists - Out Now - MarketWatch

Competitor Analysis: Cannabinoid CB1 Receptor Antagonists - Out Now MarketWatch - Acomplia (rimonabant) from Sanofi-Aventis is the only representative of this class of CB1 antagonists so far approved. While the FDA rejected approval due ...

Keywords:

acomplia, acomplia rimonabant, treatment acomplia, acomplia diet, acomplia works, rates acomplia, acomplia acomplia, acomplia panic, acomplia dosage, acomplia attainment
Health News © John Davis 2008